Highlights Cyclacel Pharmaceuticals, Inc.

Equities

CYCC

US23254L8019

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-06 pm EDT			5-day change	1st Jan Change
2.07 ^USD	+3.50%		+52.21%	-22.47%

May. 02	Cyclacel Pharmaceuticals, Inc. announced that it has received $8.000001 million in funding	CI
Apr. 30	Top Midday Gainers	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Midday Gainers	Apr. 30	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of FOMC Meeting	Apr. 30	MT
Cyclacel Pharmaceuticals Withdraws Securities Offering SEC Filing	Apr. 29	DJ
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer	Apr. 01	CI
Earnings Flash (CYCC) CYCLACEL Posts Q4 Revenue $31,000	Mar. 19	MT
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions	Dec. 18	CI
Reverse Split: 1 of 15	Dec. 17	FA
Earnings Flash (CYCC) CYCLACEL Reports Q3 Revenue $16,000	Nov. 13	MT
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	Nov. 13	CI
Earnings Flash (CYCC) CYCLACEL Posts Q2 Revenue $373,000	23-08-09	MT
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023	23-08-09	CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-06	CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-06	CI
Earnings Flash (CYCC) CYCLACEL Posts Q3 Loss $-0.42	22-11-09	MT
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2022	22-11-09	CI
Cyclacel Pharmaceuticals, Inc. Reports Preliminary Data from its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients with Solid Tumors and Lymphoma at ENA 2022	22-10-26	CI
Earnings Flash (CYCC) CYCLACEL Reports Q2 Loss $-0.46, vs. Street Est of $-0.54	22-08-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cyclacel Pharmaceuticals, Inc.

Equities

CYCC

US23254L8019

Highlights

Filters